Verici has indicated it has achieved a successful outcome from its validation study for Tuteva, which has shown strong performance in the detection of acute rejection following a kidney transplant. The finalised data will be presented at the American Transplant Congress in Jun-22 and shows a significantly higher PPV than currently available tests, in a broad patient population, giving meaningful clinically actionable data. This is a key milestone for the group, paving the way for commercial laun ....
12 May 2022
Positive performance data indicated for Tuteva
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Positive performance data indicated for Tuteva
Verici Dx Plc (VRCI:LON) | 8.0 0 0.0% | Mkt Cap: 19.4m
- Published:
12 May 2022 -
Author:
Chris Glasper -
Pages:
3
Verici has indicated it has achieved a successful outcome from its validation study for Tuteva, which has shown strong performance in the detection of acute rejection following a kidney transplant. The finalised data will be presented at the American Transplant Congress in Jun-22 and shows a significantly higher PPV than currently available tests, in a broad patient population, giving meaningful clinically actionable data. This is a key milestone for the group, paving the way for commercial laun ....